Fixation of intraluminal device

Information

  • Patent Grant
  • 11013629
  • Patent Number
    11,013,629
  • Date Filed
    Wednesday, May 1, 2019
    5 years ago
  • Date Issued
    Tuesday, May 25, 2021
    3 years ago
  • Inventors
  • Original Assignees
  • Examiners
    • Baria; Dinah
    Agents
    • Gardner, Linn, Burkhart & Ondersma LLP
Abstract
An intraluminal device and method of fixation of an intraluminal device in a mammalian lumen or hollow organ that experiences peristalsis includes a fixation system that is adapted to resist distal migration of the intraluminal device in the lumen or hollow organ. The intraluminal device has a wall surface configured to the size and shape of a mammalian lumen or hollow organ. A fixation system is adapted to resist distal migration of the body in the lumen or hollow organ. The fixation system includes a bio-absorbable material around at least one of the elongated members.
Description
BACKGROUND OF THE INVENTION

The present invention is directed to an intraluminal device and method of fixation of an intraluminal device and, in particular, a technique that enhances both fixation and removability of the device. While the invention is illustrated for use with a bariatric device and/or a metabolic device, it may be applied to other intraluminal devices positioned in a mammalian lumen or hollow organ that is subject to peristalsis, such as an esophageal stent, an anti-reflux device, a nasal gastric tube, an intestinal sleeve, and the like, including devices positioned in the fallopian tubes, vas deferens, and the like.


SUMMARY OF THE INVENTION

An intraluminal device and method of providing satiety and/or treating a metabolic disease in a recipient is disclosed in U.S. Pat. Nos. 7,846,174; 8,100,931; 8,372,087; 8,529,431; 8,672,831; 8,801,599 and 8,894,670 and published PCT Application No. WO 2015/031077 A1, the disclosures of which are hereby incorporated herein by reference in their entirety. Such devices and methods apply stress to the gastro-intestinal tract in general and in particular to the cardiac portion of the stomach of the recipient to produce satiety in the absence of food to produce satiety, and to augment fullness caused by food, and/or to treat a metabolic disease. A challenge with such devices and methods is fixation of a portion of the device against a surface of the GI tract, such as the cardiac portion of the stomach in the presence of peristalsis tending to cause distal migration of the device.


While the use of tissue ingrowth patented in the above-identified patents has been found to provide a satisfactory solution for fixation to resist distal migration, aspects of the present invention includes providing short-term fixation of the device until the tissue ingrowth providing long-term fixation is in place. Such short-term fixation is easy to carry out and capable of complete fixation over the days or weeks that it takes for the long-term fixation to occur.


Aspects of the present invention provide techniques for explantation of an intraluminal device having a wall that is configured to be positioned in a lumen. At least one core is removably connected with a portion of the wall and is positioned against lumen tissue when the wall is positioned in the lumen such that tissue envelopes of or encases the core during deployment or implantation of the device. Explantation of the device should not substantially damage the lumen of the recipient or require that the lumen be incised in order to separate the core from the lumen. Aspects of the present invention facilitate such explantation and provide techniques that may beneficially utilize such tissue encasing the connector for immediate and/or long-term fixation of an intraluminal device against distal migration caused by peristalsis.


An intraluminal device adapted to be positioned in a lumen that experiences peristalsis, according to an aspect of the invention, includes a wall configured to the size and shape of a portion of the lumen and at least one core. The at least one core is removably connected with a portion of the wall and adapted to be disconnected in situ from the portion of the wall. The at least one core is configured to be positioned against the lumen when the wall is positioned in the lumen. In this matter tissue envelopes the core during implantation of the device. The at least one core is configured to be axially removable from the tissue enveloping the core when the at least one core is disconnected from the portion of the wall in order to explant the intraluminal device from the lumen.


The at least one core may be removably connected with the portion of the wall by being configured to be axially movable with respect of another portion of the wall. The at least one core may include at least two cores that are each removably connected with a different portion of the wall by being configured to be axially movable with respect to other portions of said wall.


The at least one core may include at least two cores that are each removably connected with a different portion of the wall. The wall may be made of at least two separate wall portions that are connected together with the at least one core and the at least one core be removably connected with at least one of said at least two wall portions. The at least one core may be axially removable from the lumen in order to explant the intraluminal device from the lumen tissue enveloping the core when the core is disconnected from said at least one of the at least two wall portions. In this aspect of the invention, the at least one core may be referred to a connector, a strut, or a tension member because the at least one core applied force between the at least two wall portions which would separate in use if not for the at least one core.


A fastener may be provided that is adapted to fasten the at least one core to the lumen in order to fix the intraluminal device in the lumen. The fastener may be a suture. The fastener comprises a clip. The fastener may be adapted to be applied intraluminally. The fastener may be at an upstream end portion of the at least one core.


The at least one core may be removably connected with the portion of the wall with a removable attachment and wherein the at least one core is separable by removing the removable attachment. The removable attachment may be a severable filament. An enlarged member may be on the at least one core to space said severable filament from the wall for access to the filament. The at least one core may be coated with a bio-compatible material that extends around the at least one core.


The wall may be formed as an esophageal stent, an anti-reflux device, a nasal gastric tube, an intestinal sleeve, a bariatric device, or a metabolic disease treatment device.


A method of fixation of an intraluminal device in a lumen that experiences peristalsis, according to an aspect of the invention, includes the intraluminal device having a wall configured to the size and shape of a portion of the lumen and at least one core. The at least one core is removably connected with a portion of the wall and adapted to be disconnected in situ from the portion of the wall. The at least one core is positioned against the lumen when the wall is positioned in the lumen. In this manner, tissue envelopes the core during implantation of the device in the lumen. The at least one core is disconnected from the portion of the wall and the at least one core axially removed from the tissue enveloping the at least one core in order to explant the intraluminal device from the lumen.


The at least one core is disconnected from the portion of the wall by axially moving the at least one core with respect to said another portion of said wall. The at least one core may include at least two cores that are each removably connected with a different portion of the wall. The at least two cores may be disconnected by axially moving the at least two cores with respect to other portions of the wall.


The at least one core may be at least two cores that are each removably connected with a different portion of the wall. The wall made be made up of two or more separate wall portions that are connected together with the core. The core may be removably connected with at least one of said at least two wall portions and axially removed from the lumen in order to explant the intraluminal device from the lumen tissue enveloping the core. This includes disconnecting the cores from said least one of said at least two wall portions and separately removing the at least two separate wall portions from the lumen.


The core may be fastened to the lumen with a fastener in order to fix the intraluminal device in the lumen. The fastener may be a suture and the fastening includes applying the suture to the to the lumen. The suture may be applied around the core when applied to the lumen and a portion of lumen tissue wrapped around the core when applying the suture around the core. The fastener may be a clip. The fastener may be applied intraluminally. The fastener may be applied at an upstream end portion of said core.


The at least one core may be removably connected with the portion of the wall with a removable attachment and may be separated from the wall by removing said removable attachment. The removable attachment may be a severable filament. An enlarged member may be provided on the severable filament to space the severable filament from the wall for access to the filament.


The at least one core may be coated with a bio-compatible material that extends around the at least one core. The intraluminal device may be used as an esophageal stent, an anti-reflux device, a nasal gastric tube, an intestinal sleeve, a bariatric device, or a metabolic disease treatment device. The tissue of the lumen where the core is positioned against the lumen may be disrupted to promote the tissue enveloping the core. Such disrupting of the tissue may be using cauterization, ultrasound therapy, and/or cryro-therapy.


These and other objects, advantages, purposes and features of the present invention will become apparent upon review of the following specification in conjunction with the drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a cross section of an intraluminal device deployed in a mammalian lumen or hollow organ of a recipient, namely, a bariatric device at the gastroesophageal (GE) region of the recipient;



FIG. 2 is the same view as FIG. 1 after the device has been deployed at the GE region for a period of time, such as several weeks or months;



FIG. 3 is a side elevation of the device in FIGS. 1 and 2;



FIG. 4 is the same view as FIG. 3 of an alternative embodiment thereof;



FIG. 5 is a plan view of the esophageal portion and connector portions of FIG. 3 with the esophageal portion unrolled into a flat state;



FIG. 6 is the same view as FIG. 1 showing an alternative short-term fixation of the device;



FIG. 7 is a side elevation of a bariatric device showing the principle of removable attachment between the connector portion and the cardiac portion;



FIG. 7A is the same view as FIG. 7 illustrating an alternative embodiment thereof;



FIG. 8 is a perspective view of the device in FIG. 7 taken from the side and proximal, or top direction illustrating details of the removable attachment;



FIG. 9 is an enlarged perspective view of the portion shown at IX in FIG. 8;



FIG. 10 is the same view as FIG. 7 of an alternative embodiment;



FIG. 10A is the same view as FIG. 10 of an alternative embodiment thereof;



FIG. 11 is a perspective view taken from the side and proximal or top showing a removable attachment between the connector portion and the cardiac portion of the embodiment in FIG. 10;



FIG. 12 is a bottom or distal plan view of the removable attachment in FIG. 11;



FIG. 13 is an enlarged view of the severable knot in FIG. 12;



FIG. 14 is a side elevation of an alternative embodiment of a connector portion;



FIG. 15 is a side elevation of an alternative embodiment showing enhancement of mucosal bridging;



FIG. 16 is a sectional view taken along the lines XVI-XVI in FIG. 15;



FIG. 17 is a perspective view of a clip;



FIG. 18 is the same view as FIG. 17 of an alternative embodiment thereof;



FIG. 19 is a side elevation of an alternative embodiment of a bariatric device;



FIG. 20 is a perspective view of a retainer that is capable of short-term fixation and facilitating long-term fixation;



FIG. 21 is a sectional view taken along the lines XXI-XXI in FIG. 19;



FIG. 22 is a sectional view taken along the lines XXII-XXII in FIG. 19;



FIG. 23 is the same view of the same device of FIG. 19 of an alternative embodiment;



FIG. 24 is the same view as FIG. 16 of an alternative embodiment;



FIG. 25 is a chart illustrating relative anchoring strength of different anchoring techniques over time;



FIG. 26 is a sectional view taken along the lines XXVI-XXVI in FIG. 19;



FIG. 27 is a plan view of an alternative embodiment of a clip;



FIG. 28 is the same view as FIG. 24 showing the clip in FIG. 27 applied;



FIG. 29 is a side elevation of an alternative embodiment of an intraluminal device;



FIG. 30 is a sectional view taken along the lines XXX-XXX in FIG. 29;



FIG. 31 is a sectional view taken along the lines XXXI-XXXI in FIG. 30;



FIG. 32 is a view of the device in FIG. 29 illustrating assembly thereof;



FIG. 33 is an alternative view of the device in FIG. 29 illustrating assembly thereof;



FIG. 34 is a side elevation of an alternative embodiment of an intraluminal device;



FIG. 35 is a side elevation of an alternative embodiment of an intraluminal device;



FIG. 36 is a side elevation of an alternative embodiment of an intraluminal device;



FIG. 37 is a perspective view of an intraluminal device, according to an embodiment of the invention;



FIG. 38 is a sectional view taken along the lines XXXVIII-XXXVIII in FIG. 37;



FIG. 39 is a side elevation view of a distal end of an endoscope with a fastener therein;



FIG. 40 is the same view as FIG. 39 with the fastener extending distally from the endoscope;



FIG. 41 is an end elevation view of the endoscope in FIG. 39;



FIG. 42 is an enlarged view of the fixation system showing the portions of the endoscope tool engaging fastener portions with tissue on opposite sides of the connector;



FIG. 43 is the same view as FIG. 42 with the endoscopic tool pulling the tissue and fastener portions around the connector;



FIG. 44 is the same view as FIG. 43 with the endoscopic tool moving away from the fastener after applying a band and severing the fastener portions from a stem;



FIG. 45 is the same view as FIG. 38 of an alternative embodiment thereof;



FIG. 46 is a side elevation view of the distal end of an endoscope with the fastener shown in FIG. 45 internal to the endoscope;



FIG. 47 is the same view as FIG. 46 showing the fastener extending distally from the endoscope;



FIG. 48 is the same view as FIG. 42 of the embodiment in FIGS. 45-47;



FIG. 49 is the same view as FIG. 43 of the embodiment in FIGS. 45-47;



FIG. 50 is the same view as FIG. 44 of the embodiment in FIGS. 45-47;



FIG. 51 is an alternative embodiment of an intraluminal device; and



FIG. 52 is the same view as FIG. 51 of another alternative embodiment of an intraluminal device.





DESCRIPTION OF THE PREFERRED EMBODIMENTS

Referring now to the drawings and the illustrative embodiment depicted therein, an intraluminal device, such as a bariatric device or a metabolic disease treatment 10, has a wall 12 defining an esophageal portion 14 that is configured to the size and shape of a portion of a mammalian lumen or hollow organ, namely, the esophagus, a cardiac portion 16 that is configured to the size and shape of a separated portion of mammalian lumen or hollow organ, namely, the cardiac portion of the stomach and a connector 18 connecting esophageal portion 14 and cardiac portion 16 (FIGS. 1-5). While illustrated as a bariatric device, it should be understood that that principles of the invention are applicable to other intraluminal devices that are positioned in a lumen or hollow organ that experiences peristalsis, such as an esophageal stent, an anti-reflux device, a nasal gastric tube, an intestinal sleeve, and the like. Also, the invention may be applied to a metabolic disease treatment device and method as disclosed in commonly assigned International Patent Application Publication No. WO 2015/031077 A1, the disclosure of which is hereby incorporated by reference in its entirety.


As can be seen in FIGS. 1 and 2, intraluminal device 10 is positioned at the gastroesophageal region with the esophageal portion 14 in the esophagus, the cardiac portion 16 at the cardiac portion of the stomach and at least a portion of connector 18 extending through the gastroesophageal (GE) junction. In the illustrated embodiment, connector 18 is made up of two elongated filaments 20a, 20b which are in tension and may be referred to as struts. As can be seen by comparing FIGS. 1 and 2, with device 10 fixed at the gastroesophageal region to cause body mass loss, mucosa (which may include submucosa and even muscular) tissue bridges over at least one of the two struts 20a, 20b as shown in FIG. 2 after device 10 has been positioned in the GE region. The bridging tissue can fuse with time sufficiently to achieve significant loss of excess body mass making it difficult to explant intraluminal device 10. Also, as will be discussed in more detail below, tissue bridging of struts 20a, 20b may provide long-term fixation of device 10, alone or in combination with other functions in accordance with the principles set forth in commonly assigned U.S. Pat. No. 8,894,670 B2. In particular, the struts correspond to the bridge in the '670 patent and the spaces between the struts correspond to the openings adjacent the bridge in the '670 patent so that the tissue bridging over the struts implements mucosal capture patented in the '670 patent.


Fixation of intraluminal device 10 against distal migration includes a fixation technique 22 that fastens esophageal portion 14 with the esophagus with a fastener such as a tissue penetrating fastener 24. A looped filament 26 extending proximally from esophageal portion 14 is captured with fastener 24 engaging the wall of the esophagus by the fastener. The loops in the looped filament are positively engaged by the fastener so that the esophageal portion 14 is firmly fixed to the esophagus by the fastener. The number of loops can vary from one to many and can be any size or shape as long as they are a closed polygon. In the illustrated embodiment, fastener 24 is an endoscopically deployed clip marketed by Ovesco and described in detail in U.S. Pat. No. 8,721,528 for an ENDOSCOPE CAP, the disclosure of which is hereby incorporated herein by reference. Also, although two loops and penetrating fasteners are illustrated, one or more than two may be used.


Fixation technique 22 is intended to provide at least temporary fixation to maintain device 10 in position at the GE region of the recipient with cardiac portion 16 engaging the cardiac region of the stomach while permanent fixation develops. Looped filament 26 may be at least partially elastic in order to be slightly stretched when fastener 24 is deployed to maintain upward pressure on cardiac portion 16 after deployment. Looped filament 26 may be at least partially bioabsorbable, or resorbable, so that it, along with fastener 24, may fall away after permanent fixation occurs as seen in FIG. 2. Looped filament 26 may be made from monofilament or braided filament. An enlarged portion 28 of filament 26 may be provided and fastener 24 applied at or adjacent tissue of the esophageal wall that is drawn over the enlarged portion 28 by suction. Alternatively, the fastener 24 may be applied adjacent the enlarged portion 28, such as distal the enlarged portion. The enlarged portion and the loops defining looped filament 26 provide engagement between the mechanical fastener and the looped filament to prevent the looped filament from pulling away from the fastener. In the illustrated embodiment, enlarged portion 28 is a bead. As illustrated in FIG. 4, it may be desirable to position enlarged portion 28 as close as possible to esophageal member 14 to avoid entanglement between a retainer filament 30 discussed below and another retainer filament (not shown) that extends proximally from esophageal member 14.


A retainer filament 30 may be temporarily connected with the looped filament 26 and extending external the recipient of the device from the esophagus. Retainer filament 30 allows the physician or other healthcare worker the ability to position bariatric device 10 properly at the GE region and to apply tension to looped filament 26 until fastener 24 is applied. As retainer filament 30 is merely looped proximally to looped filament 26, it can be easily retraced by pulling on one side of the loop. Looped filament 26 is connected directly with the mesh 32 that provides a structure to bariatric device 10. This allows the looped filament to apply proximal axial force to mesh which force is then distributed over wall 12 without causing a narrowing of esophageal portion 14 as may occur if the looped filament were to be connected with a removal suture (not shown) that encircles esophageal portion 14 proximally and is used to remove device 10. If a proximal force were to be applied to such removal suture, the diameter of esophageal portion 14 may be reduced upon fixation thus counteracting mucosal capture and/or tissue ingrowth of the wall of the esophageal portion to the esophageal wall. While the application of proximal axial force to such removal suture, or ring, may be a useful action to explant intraluminal device 10, it would not be useful in providing fixation.


Thus, the direct connection of looped filament 26 to mesh 32 allows proximal axial force to be applied to esophageal portion 14 without inducing a radially inward force tending to pull wall 12 away from the esophagus wall. While looped filament 26 is shown in FIG. 1 and FIG. 3 connected with a proximal end portion of mesh 32, it could also be connected at a central or distal portion of the mesh as shown in FIG. 4. While filament 26 could extend from the interior of esophageal portion 14, it could also extend from an outer surface of the esophageal member wall, as shown in FIG. 4, thereby ensuring that any tension force on filament 26 tends to pull the esophageal member wall toward the esophagus wall. Also, as shown in FIG. 4, cardiac portion 16 may include a transition zone 17 adjacent its proximal opening 19 in order to resist any irritation of the tissue of the cardiac portion of the stomach in accordance with the principles set forth in commonly assigned International Patent Application Publication No. WO 2012/044917, the disclosure of which is hereby incorporated herein by reference in its entirety.


In an alternative technique illustrated in FIG. 6 temporary fixation is provided by a tissue penetrating fastener in the form of sutures 24′. Each suture 24′ is passed through the wall of esophageal portion 14 and at least partially through the wall of the esophagus of the recipient. The suture may be applied endoscopically, such as by using an automated suture device that is commercially available such as one marketed by Apollo Endosurgery. The suture is preferably made from an absorbable material so that it dissolves over time as more permanent fixation from tissue capture takes over. In the embodiment used in FIG. 6, looped filament 26 is used to transmit the retaining force from retainer filament 30 to the esophageal member 14 but does not form a part of temporary fixation. It would be possible to attach retainer filament 30 directly to esophageal portion 14.


Fixation of device 10 against distal migration includes temporary fixing, such as using fixation 22, and long-term fixing from wall characteristics that fixes the wall to the GE region through growth of tissue, such as using tissue ingrowth zones 34 formed in wall 12.


Tissue ingrowth zones 34 are openings in the cover 33 of biocompatible material, such as silicone, over mesh 32, which openings allow tissue to grow over members of the mesh. As shown in FIG. 5 and as disclosed in U.S. Pat. Application Publication No. 2014/0121585 entitled INTRALUMINAL DEVICE AND METHOD WITH ENHANCED ANTI-MIGRATION, the disclosure of which is hereby incorporated herein by reference, zones 34 are more effective if spaced apart a distance “C” in the direction of peristalsis on an order of magnitude of at least the wavelength of the peristaltic wave. Long-term fixation using ingrowth openings 34 may be removed to explant device 10, such as by cauterizing the tissue in the mucosal capture zones 34 and by placing an inward radial force on esophageal portion 14 such as by applying a proximal force on the removal suture (not shown) in order to remove device 10. Also, an over tube, of the type known in the art, may be inserted between esophageal portion 14 and the wall of the esophagus to further separate wall 12 from the tissue of the esophagus. Other techniques for removing mucosa from openings 34, such as mechanical severing of the tissue, will be apparent to the skilled artisan.


Tissue at or adjacent the GE junction, which includes tissue immediately above and below the sphincter, may bridge over one or both struts 20a, 20b of connector portion 18 at the GE junction as seen in FIG. 2 after bariatric device 10 has been deployed for several weeks or months. Such tissue bridging over struts 20a, 20b may be difficult to remove, such as by merely placing a radial inward force on the struts. It will be appreciated that struts 20a, 20b could not be readily axially displaced with esophageal portion 14 close to the GE junction and cardiac portion 16 against the stomach wall because esophageal portion 14 and cardiac portion 16 are much larger than either strut 20a, 20b and, therefore, could not be pulled through the opening in the bridging tissue. In order to remove struts 20a, 20b to explant device 10, struts 20a, 20b of connector portion 16 of wall 12 are axially displaced, or pulled, from the gastroesophageal junction to remove the connector from the bridging tissue to remove the bariatric device.


This could at least theoretically be achieved by physically severing the struts, such as using an argon beam coagulator, or the like. In the illustrated embodiments, such axial displacement of the struts is achieved by making struts 20a and 20b separable from the portion of the device wall 12 defining cardiac portion 16 and by separating the struts from the device wall as seen in FIG. 7 or by making struts 20c and 20d separable from the portion of the device wall defining esophageal portion 14 and separating the struts from the device wall as seen in FIG. 7A. Struts 20a, 20b, 20c, 20d are adapted to be separated by being removably attached with a removable attachment 42 to wall 12. The struts can be separated by removing the removable attachment.


Once free of the cardiac portion 16, struts 20a, 20b may be axial withdrawn, or pulled, proximally through the bridging tissue of the GE junction by axial proximal displacement of esophageal portion 14 in the manner discussed above. Once the struts are withdrawn, the esophageal portion 14 can be retracted proximal, using a removal suture (not shown), or the like. The cardiac portion 16 can be removed from the stomach by drawing it into an over tube inserted in the esophagus or other such method. Once free of esophageal portion 14, struts 20c, 20d may be withdrawn, or pulled, proximally through the bridging tissue of the GE junction by axially distal displacement of cardiac portion 16 into the stomach where it can be removed as discussed above. The esophageal portion 14 can be withdrawn proximally. While the embodiment disclosed in FIG. 7A requires that a force be applied to the cardiac portion 16 to axially separate the struts 20c, 20d from the bridging tissue, an advantage of this embodiment is that the removable attachment 42 is located at the esophageal portion 14 where it is more easily accessed in order to remove the attachment.


Struts 20a, 20b, 20c, 20d may be each formed from a single continuous metallic filament 38, such as Nitinol or stainless steel that is twisted from distally to proximally as shown in FIG. 4. As filament 38 is wound, several openings 40 may be formed in struts 20a, 20b, 20c, and 20d as will be described below. Ends of filament 38 may be woven with the mesh 32 of esophageal portion 14 or of the mesh of the cardiac portion 16 or otherwise attached as seen in FIG. 5. Struts 20a, 20b, 20c, 20d are coated with silicone or other biocompatible material to ease axial withdrawal from the tissue bridging the struts. Also, struts 20a, 20b, 20c, 20d may have an optional elastic portion (not shown) to enhance proximal force placed on cardiac portion 16 to ensure satiety. Also, struts 20a, 20b, 20c, 20d may include a therapeutic agent eluting coating that applies a therapeutic agent, such as an anesthesia, or the like. This coating may elute the agent for a limited period, such as two weeks, after deployment, to ensure pain-free embedding of the struts in the recipient. Alternatively, an agent-dispensing reservoir could be at a distal portion of esophageal portion 14 to dispense a controlled amount of a therapeutic agent, such as an anesthesia to the tissue engaging the struts. In addition to the struts, a therapeutic agent eluting coating may be applied to the area surrounding tissue ingrowth zones 34 and perhaps other areas of device 10. For example, a different type of agent, such as to encourage tissue fibrosis and ingrowth, may be eluted to encourage earlier and stronger long-term fixation.


In one embodiment, removable attachment 42 includes a separable portion of struts 20a, 20b, 20c, 20d extending along the surface of wall 12 as seen in FIGS. 8 and 9. Openings 40 are arranged to register with intersections 44 in the portion of mesh 32 of wall 12. Removable attachment 42 is illustrated as a chain stitch 46 between one or more openings 40 and corresponding intersections 44. The stitch is made with a filament, such as high-strength suture material, or the like. The advantage of a chain stitch, which is known in the art, is that it can be completely removed by severing its filament, such as with an endoscopic scissors or heating device, at any place such along the filament. Once removable attachment 42 is severed at separable portions of both struts 20a, 20b, esophageal portion 14 can be proximally withdrawn thus axially liberating the struts from the captured tissue at the GE junction. Once removable attachment 42 is severed at separable portions of both struts 20c, 20d cardiac portion 16 can be distally withdrawn thus axially liberating the struts from the captured tissue at the GE junction.


As discussed above, cardiac portion 16 will be in the stomach and can be removed transorally. In addition to a separate chain stitch 46 for each strut as shown, it is possible to extend the chain stitch to encompass separable portions of both struts (not shown) so that the chain stitch filament need be severed only once to break both struts free of the wall portion. Also, it is possible that tissue bridging may only occur at one of strut pairs 20a, 20b, such as strut 20b or one of strut pairs 20c, 20d positioned against the GE sphincter at the angle of HIS. As such, removable attachment 42 may be provided for only one strut.


In an alternative embodiment, an intraluminal device 110 includes a wall 112 defining an esophageal portion 114 configured to the size and shape of a portion of the esophagus, a cardiac portion 116 configured to the size and shape of a portion of the cardiac portion of the stomach and a connector 118 (FIGS. 10-13) of which at least a portion passes through the GE junction. Tissue ingrowth openings 134 provide long-term fixation. Intraluminal device 110 is essentially the same as device 10 except that connector portion 118 is removably connected with wall 112 by an alternative removable attachment 142. In FIG. 10, separable portions of struts 120a, 120b making up connector portion 118 extend over some of intersections 144 of the mesh 132 of cardiac portion 116 and under other ones of the intersections 144 at cardiac portion 116 as seen in FIGS. 10-13. In FIG. 10A, separable portions of struts 120c, 120d extend over some intersections of the mesh of esophageal portion 114 and under other ones of the intersections at the esophageal portion 114 of wall 112.


Removable attachment 142 includes a severable knotted filament 150 at a distal end of each strut secures an end of the separable portion of the strut to the wall as seen in FIGS. 11-13. In this manner, severing of filament 150 allows each strut to pull away from the wall portion. The severable filament 150 may include an extender, such as a bead 152, to enhance access to the filament to assist in severing the filament. Bead 152 is strung on filament 150. Filament 150 may extend between both separable ends of the struts so that the filament needs to be severed at one place to free both struts from the wall portion.


It should be understood that the tissue bridging over struts 20a, 20b, 20c, 20d, 120a, 120b, 120c, 120d which are elongated filaments that provide a wall characteristic that fixes the wall of the respective struts to the GE region through growth of tissue, can be useful as all or part of long-term fixation of device 10, 110. Such long-term fixation may be enhanced by adding length to similar struts 220a, 220b shown in FIG. 14. This may be accomplished by providing a knee to the strut, such as branching to the filaments as seen in FIG. 14. This may be accomplished by leaving the filaments non-twisted so that each filament forms a separate bridge that bows outwardly. Once the attachment to the wall portion (not shown in FIG. 14) is severed, the multiple filament branches to the strut can be individually pulled through the same opening in the mucosa caused by the bridging. Struts 20a, 20b, 20c, 20d 220a, 220b, 220c, 220d can have an outward knee to further engage the mucosa to promote tissue bridging.


Also, short-term and/or long-term fixation using the struts can be enhanced by applying tissue penetrative fasteners in the form of retainers 54 to the bridging mucosa (FIGS. 15-17). Retainers 54 include a U-shaped body having a pointed end with barbs 55. This allows the retainer to be inserted through the mucosa onto the muscular and the barbs to hold the retainer in place. Retainers 54 can be bioabsorbable so that they fall away after the passage of time when mucosal bridging is secure. Alternatively, retainers 154 include coupled U-shaped portions, each with barbs 155 in order to enhance attachment to the muscular as seen in FIG. 18. Application of suction to the esophagus of the recipient will tend to cause the tissue of the EG junction to come together around the respective strut to assist in placement of retainers 154 to bring the tissue portions together around the strut to facilitate tissue capture of the strut using the principles disclosed in commonly assigned U.S. Pat. No. 8,894,670, the disclosure of which is hereby incorporated herein by reference in its entirety.


Other forms of tissue penetrating fasteners can be used, such as EZ clip or a quick-clip, both available from Olympus. In addition to promotion of tissue bridging over the strut(s) 20a, 20b, 20c, 20d, 120a, 120b, 120c, 120d, the retainers 54, 154 may provide resistance to distal migration of esophageal member 14. This helps to provide tension on the struts, thus ensuring cardiac member 16, 116 is in contact with the cardiac portion of the stomach. Thus, clip 54, 154 may provide both immediate short-term fixation of the bariatric device and promote long-term fixation via fusion of tissue bridging struts 20a, 20b, 20c, 20d, 120a, 120b, 120c, 120d.


An intraluminal device 210 is shown in FIGS. 19-23 in which another technique is shown for fixation of the intraluminal device against peristalsis in the lumen. Device 210 includes a wall 212 defining an esophageal portion 214 having a size and shape corresponding to a portion of the esophagus at the GE region, a cardiac portion 216 having a size and shape corresponding to a portion of the cardia or a cardiac portion of the stomach, and a connector 218 connecting the esophageal portion to the cardiac portion. At least a portion of connector 218 passes through the GE junction. Connector 218 is made up of two elongated struts 220a, 220b, both of which pass through the GE junction. The struts elongated shape provides a wall characteristic that provides, at least in part, long-term fixation of wall 212 to the GE region though growth of tissue around each strut. Struts 220a, 220b include a biocompatible coating, such as silicone, or the like, that allows the struts to be axially separated from the GE junction once severing of the removable connector (not shown in FIG. 19) separates the strut from the wall portion 212 in the manner previously described.


An alternative issue penetrating fastener 256 around each strut 220a, 220b includes a series of tissue penetrating barbs 257 that are capable of penetrating mucosa, submucosa, and/or muscular at the GE junction when pressed against the tissue. Penetrating barb 257 may have fishhook, or arrowhead, features to avoid withdrawal of the barbs once inserted. Fastener 256 may be formed around the strut as part of manufacture or may be a separate device as shown in FIG. 20 having a slit that allows it to be positioned around the strut at deployment.


In addition to the dimensions of each strut providing a wall characteristic that causes tissue to grow around the strut, each fastener 256 may have a wall characteristic 259 facing away from the tissue of the GE junction that enhances long-term fixation of wall 212 to the GE region through promoting growth of tissue around the respective strut. Wall characteristic 259 may be a roughened or fenestrated surface, a surface impregnated with a tissue growth agent, or the like. Wall characteristic 259 may include bars similar to barbs 257 such that application of suction to the esophagus of the recipient tends to draw the tissue of the GE junction around the wall characteristic 259 where it is ensnared by the barbs of wall characteristic 259 to further enhance short-term fixation. Fastener 256 may be made in whole or in part from a bioabsorbable material to resorb after tissue grows around the strut to provide long-term fixation of device 210. The resorption of the fastener 256 avoids fastener 256 from impeding axial withdrawal of the struts for device explantation.


Another tissue penetrating fastener 258 having tissue penetrating barbs 257 may be at a portion of esophageal member 214, such as at its distal rim, in order to provide additional temporary fixing of device 210 at the GE region. Fastener 258 is shown formed or otherwise attached to a distal rim of esophageal portion 214 but could be located at any portion of esophageal portion 214. Fastener 258 only provides temporary fixing of device 210 and therefore does not include a wall characteristic 259 that enhances long-term fixing of wall 212 to the GE region. Fastener 258 is made in whole or in part from bioabsorbable material in order to resorb after long-term fixation is in place to avoid interference with explantation of device 240.


As seen in FIG. 23, device 210 may include a fastener 256 at one or both struts 220a, 220b making up connector 218, but not include a fastener 258 at the esophageal portion 214. Of course device 210 may include a tissue penetrating fastener 258 without a combination temporary and permanent fixing device 256 since the elongated slender nature of struts 220a, 220b are a wall characteristic that fixes wall 212 to the GE region through growth of tissue to provide long-term fixation.


An alternative retainer 354 shown in FIG. 24 is a clip that closes around the strut 20a, 20b, 20c, 20d, 2120a, 120b, 120c, 120d, or which only struts 20a and 20b are shown, after the device 10 is positioned at the GE region. Clip 354 may be spring-loaded or made from memory material to close around the strut upon being positioned in the tissue or may be mechanically deformed by a mechanism that is endoscopically deployed. Suction applied to the esophagus of the recipient may be applied to assist in drawing tissue around the struts to facilitate a clip being inserted into the tissue.



FIG. 26 illustrates another tissue penetrating fastener 258b that may be used in whole or in part for short-term fixation of device 210 against distal migration. Fastener 258b may be placed at a proximal end portion of esophageal portion 214. Fastener 258b has barbs 257b that at least partially penetrate the tissue of the esophagus to provide short-term fixation. Fastener 258b may be made in whole or in part from a resorbable material in order to be absorbed in the recipient after long-term fixation has occurred. Barbs 257b are illustrated as being distally angled so that device 210 can be adjusted proximally during deployment without impediment from the bars which are still capable of resisting distal migration.



FIGS. 27 and 28 illustrate yet another alternative tissue penetrating retainer 454 that can be used for short-term fixation of the intraluminal device 10, 110, 210. Retainer 454 is positioned along a strut up against the esophageal portion. Retainer 454 is barbed to be retained. In the tissue of the GE junction as shown in FIG. 28 includes a tissue attachment portion 454a. After retainer 454 is over the strut and inserted into the tissue (either as part of positioning the device or after the device is positioned), suction may be applied to the esophagus which will tend to draw tissue around the strut where it will be retained by barbs or other surface of tissue attachment portion 454a.


Thus, it is seen that aspects of the present invention encompass short-term and long-term fixation of an intraluminal device, such as a bariatric device, in a lumen, such as the gastro-esophageal region of the recipient. The long-term fixation uses the body's response to the presence of the device to provide long-term fixation. Short-term fixation, such as one or more tissue penetrating fasteners, provide fixation of the device while long-term fixation develops. Once long-term fixation develops, the short-term fixation may slough off or be absorbed as it is no longer needed. Even multiple different types of long-term fixation may be provided in order to provide optimal fixation at different times after deployment. For an example, FIG. 25 illustrates relative fixation, shown on the Y-axis for different time intervals after deployment, shown on the Y-axis. When the device is deployed, at the origin of the graph, temporary fixation F maintains the intraluminal device in place. After deployment, the tissue ingrown TI begins to develop and increases over time. Sometime after deployment, temporary fixation F may be eliminated, such as by absorption of resorbable sutures or filament loops, as depicted by the dashed horizontal line. By that time, the tissue ingrowth TI should be sufficiently strong to provide long-term fixation. An additional form of long-term fixation may be provided by mucosal capture MC around the struts of the bariatric device. While the mucosal capture MC may take longer to develop than the tissue ingrowth TI, it may provide long-term fixation even if the tissue ingrowth fixation TI weakens over time.


It should be understood that FIG. 25 is intended to illustrate conceptual relationships and is not based upon physical measurements. It should also be understood that the timeline in FIG. 25 may be measured over days, weeks or months. However, it is expected that tissue ingrowth TI or mucosal capture MC should be sufficient to provide fixation by itself within about four (4) days to one or more weeks.


It may also be possible to eliminate tissue ingrown TI and rely exclusively on mucosal capture MC in order to provide long-term fixation. Such alternative may include using one of the illustrated retainers around one or both struts in order to provide short-term fixation while long-term fixation develops, such as by mucosal capture MC around each of the struts. By providing both short-term and long-term fixation at the struts, the intraluminal device should be simpler to deploy and explant. Deployment may occur by the insertion of a retainer clip at one or both struts or even by a self-deploying retainer that penetrates tissue at the GE junction upon positioning of the device in the lumen of the recipient. With long-term fixation provided at the struts alone, the device can be explanted by separating the separable struts and axially retracting the struts from the GE junction by proximally withdrawing the esophageal member from the esophagus. The cardiac member can then easily be retrieved from the stomach. Because tissue ingrowth is not employed in such embodiment, there is no need to remove tissue from the tissue ingrown zones.


The intraluminal device 10, 110, 210 may be made adjustable in order to adjust or titrate the amount of stress on the cardiac portion of the stomach, such as by using a bladder or bladders on the proximal surface of the cardiac portion using the principles disclosed in International Application Publication No. WO2015/031077, the disclosure of which is hereby incorporated herein by reference in its entirety. Besides providing for adjustability, such bladder(s) may be filed with a fluid made of a lighter-than-air gas, such as helium, hydrogen, or the like, in order to assist in urging the cardiac member against the cardiac portion of the stomach in order to at least partially provide short- or long-term fixation.


An intraluminal device 500 is adapted to be positioned in a lumen that experiences peristalsis such as shown in FIG. 31. The lumen may be an esophagus, a colon, nasal passage, or other lumen that experiences peristalsis and therefore is subject to distal and/or proximal migration. Device 500 includes a wall 502 that is configured to the size and shape of a portion of the lumen in which the device is intended to be implanted and includes a first separable wall portion 502a and second separable wall portion 502b (FIG. 29). Device 500 further includes a core 504. Core 504 is removably connected with wall portion 502a or 502b and adapted to be disconnected in situ from the portion 502a of the wall as illustrated by the arrows in FIG. 29. FIG. 32 illustrates each core 504 fixedly connected with wall portion 502a and removably connected with wall portion 502b in a manner that the core can be disconnected in situ from wall portion 502b. FIG. 33 illustrated each core 504 fixedly connected with wall portion 502b and removably connected with wall portion 502a in a manner that the core can be disconnected in situ from wall portion 502a.


Core 504 is an elongated narrow body that is capable of tissue, such as mucosa, lining the lumen encompassing or bridging the body of the core during deployment or implantation of the intraluminal device in the lumen. The core can be of any cross sectional shape, can be rigid or flexible, can be a tension member or not and can be made of a variety of materials such as suture material, medical grade titanium, nitinol coated with a biological grade cover, or the like. Examples of cores are struts 20a, 20b in FIG. 1.


Core 504 is configured to be positioned against the lumen when wall 502 is positioned in the lumen. In this matter tissue envelopes the core during implantation of the device as seen in FIG. 31. The tissue of the lumen where the core is to be positioned against the lumen may be disrupted to promote the tissue enveloping the core. Such disrupting of the tissue may be by using cauterization, ultrasound therapy and/or cryro-therapy or the like. Core 504 is configured to be axially removable from the tissue enveloping the core when core 504 is disconnected in situ from the portion 502a and/or 502b of wall, as shown by the arrows in FIG. 29 in order to explant the intraluminal device 500 from the lumen.


The two separate wall portions 502a and 502b that are connected together with cores 504 in order to form wall 502 of intraluminal device 500. Cores 504 be removably connected with at wall portions 502a, 502b. Cores 504 may be axially removable from the lumen encompassing each core, as seen in FIG. 31 in order to explant the intraluminal device from the lumen when the core 504 is disconnected from either wall portion 502b in the configuration illustrated in FIG. 32 or wall portion 502a in the configuration illustrated in FIG. 33. In this embodiment with two or more separable wall portions connected together with the cores, the cores may be referred to as connectors, a struts, or a tension members because the cores transfer force between the wall portions which would otherwise separate in situ.


A fastener 506 may be provided to fasten 504 core to the lumen in order to fix intraluminal device 500 in the lumen. The fastener may be a suture 508 as illustrated in FIG. 30 and FIG. 31. Suture 508 is applied around 504 core when applied to the lumen. A portion of lumen tissue is wrapped around core 504 when applying the suture around the core. This provides immediate fixation of the intraluminal device in the lumen against migration. Also, the wrap of the tissue around the core speeds the tissue enveloping the core to provide long term fixation of the intraluminal device. The fastener may be adapted to be applied intraluminally. In the illustrated embodiment, suture 508 is an intraluminal suturing device marketed by Apollo Endosurgery.


As best seen in FIG. 30 fastener 506 is at an upstream end portion of the core with respect to predominant peristaltic movement in the lumen. With the fastener as close as possible to the connection of the core with wall portion 502a there is minimal sippage of core 504 with respect to fastener 506 before wall portion 502a engages the fastener and thus restricts further movement.


Alternatively, fastener 508 may be a clip such as clip 54, 154, 354, or 454. It is also possible to have only one core 504 instead of a pair and rely on the shape of the lumen to maintain the overall form of the intraluminal device as shown in FIG. 34. Also, more than two separate wall portions 502a, 502b, and 502c and be used as also shown in FIG. 34.


Core 504 may be connected with wall portion 502 a and/or 502b with a removable attachment 42, 142 (FIGS. 8-13). Core 504 is separable from the respective wall portion by removing the removable attachment 42, 142. The removable attachment may be made of a severable filament 150. An enlarged member such as a bead 152 may be on the at least one core to space severable filament 150 from the wall portion for access to the filament as best seen in FIG. 13. The at least one core may be coated with a bio-compatible material, such as silicone that extends around the at least one core. Wall 502 may be formed into an esophageal stent, an anti-reflux device, a nasal gastric tube, an intestinal sleeve, a bariatric device, a metabolic disease treatment device, or the like.


An intraluminal device 600 has a unitary wall 602 with at least one core 604 that is removably connected with a portion 602a of wall 602 by being configured to be axially movable with respect of another portion 602b of the wall (FIG. 35). The at least one core may include at least two cores 604 that are each removably connected with a different portion of the wall 602′ by being configured to be axially movable with respect to other portions of wall 602′ as seen in FIG. 36. With core(s) 604 in the axial extended position illustrated in FIGS. 35 and 36 the intraluminal device 600, 600′ is deployed to the lumen. A fastener 606 is applied to each core in the manner previously described. Optionally, a suction may be applied to the interior of wall 602, 602′ to assist in drawing the mucosa of the lumen around the core. After device 600, 600′ has been implanted for a period of one week to a number of months, sufficient to perform its intended function, and is ready to be explanted, core(s) 604 are removed from the tissue encompassing the core(s). This is accomplished by endoscopically severing the filament making up attachment 42, 142 and retracting the core(s) into wall portion 602b, which is upward in FIGS. 35 and 36. This axially withdraws the core(s) from the tissue encompassing the core so that device 600, 600′ can be explanted without needing to incise the tissue encompassing the core.


As can be seen in FIGS. 37 and 38, an intraluminal device 710 is positioned at the gastroesophageal region with the esophageal portion 714 in the esophagus, the cardiac portion 716 at the cardiac portion of the stomach and at least a portion of connector 718 extending through the gastroesophageal (GE) junction. In the illustrated embodiment, connector 718 is made up of two elongated filaments 720a, 720b, which are in tension and may be referred to as struts. A fixation system 722 is configured to resist distal migration of intraluminal device 710 within the lumen or hollow organ in which it is deployed. Resisting distal migration is challenging in the presence of peristalsis which tends to cause such distal migration. Fixation system 722 includes long-term fixation that develops over a length of time and immediate fixation 726 that resists distal migration of the wall 712 at least while the long-term fixation develops. Long-term fixation may be provided by a characteristic of wall 712 that facilitates tissue ingrowth, such as tissue ingrowth openings, tissue capture of connectors 720, or the like. As can be seen in FIG. 37 with device 710 fixed at the gastroesophageal region to cause body mass loss, mucosa (which may include submucosa and even musculara) tissue bridges over at least one of the two struts 720a, 720b after device 710 has been positioned in the GE region for a period of time on the order of weeks. The bridging tissue can thus fuse within the time necessary to achieve significant loss of excess body mass making it difficult to explant intraluminal device 710. Also, as will be discussed in more detail below, tissue bridging of struts 720a, 720b may provide long-term fixation of device 710, alone or in combination with other functions.


Immediate fixation system 722 is made up of one or more fasteners 726 which can provide fixation immediately upon deployment of device 710 and continue to provide fixation while long-term fixation develops over days, weeks, or months. However, it should be understood that immediate fixation 722 may provide the entire fixation of intraluminal device 710 against distal migration for the duration of the device being deployed to the lumen or hollow organ. Also, immediate fixation system 722 brings tissue portions together over one or both struts 720a, 720b, thus promoting formation of long-term fixation by contact between the tissue portions.


Immediate fixation system 722 includes one or more fasteners 726 having portions 730a, 730b adapted to engage tissue of the lumen or hollow organ on opposite sides of connector filament 720a or 720b and joins the tissue around the connector. Each fastener portion includes barbs 732 so that a force on the fastener portion in the direction of the lumen or hollow organ wall will penetrate the tissue thereof, as best seen in FIG. 42, while a force in the opposite direction will pull tissue portions around the connector filament, as best seen in FIG. 43. A band 734 is adapted to bias fastener portions 730a, 730b together and join tissue portions together around the connector filament. Thus, band 734 brings together the tissue that is engaged by both fastener portions 730a, 730b and keeps the connector 720a, 720b firmly engaged by fastener 726 and the tissue of the lumen or hollow organ, as seen in FIGS. 38 and 44.


Fastener 726 is configured to be delivered from a channel 736 of an endoscope 738. Each fastener portion 730a, 730b has a surface feature 740, such as a bead, bend, or the like, to retain band 740 firmly engaged with fastener portions 730a, 730b. Each fastener portion 730a, 730b is joined with a respective stem 742a, 742b that extends out the opposite proximal end of channel 736. Stem 742a, 742b is joined with fastener portion 730a, 730b by a frangible connection so that the fastener portion may be separated from the stem in situ, such as by rotation of the stem where it exits channel 736 proximally, or the like, to place stress on the frangible connection to separate the connection. Also, once the fastener portions are deployed and the stems 742a, 742b are withdrawn, the physician can reload the endoscope with new fastener portions at the proximal end of channel 736 without withdrawing the endoscope from the recipient of the endoscopic device.


A band dispenser 744 is at the distal end of endoscope 738. Band dispenser 744 may have a number of bands 734 stored in grooves 746 with each band separately dispensed by proximal movement of dispenser filaments 748. By supporting a number of bands, band dispenser 744 can deploy bands for a number of fasteners 28 without needing to be removed from the recipient. Such band dispensers are well known in the art, such as marketed by Ovesco Endoscopy and as disclosed in commonly assigned U.S. Pat. Application Publication No. 2015/0182239 A1, the disclosure of which is hereby incorporated herein by reference in its entirety.


An alternative fixation system 822 includes an immediate fixation system having one or more fasteners 826 (FIGS. 45-50). Fasteners 826 are dispensed from a channel 835 of endoscope 834 and has fastener portions 830a, 830b that are joined by a bridge 850. Faster portions 830a, 830b have barbs 832 and are biased away from each other. When in channel 835 the fastener portions may be compressed together as illustrated in FIG. 46, but, when dispensed distally, the fastener portions are allowed to expand away from each other as seen in FIG. 47. Force placed on the fastener 828 causes portions 830a, 830b into engagement of tissue of the lumen or hollow organ as seen in FIG. 48. Once engaged with the tissue, the fastener portions 830a, 830b are pulled away from the wall of the lumen or hollow organ and a band 834 applied around the fastener portions, as best seen in FIG. 49. The band 834 is dispensed as shown in FIG. 50. While it may be possible to deploy fastener 826 without the use of a band because of bridge 850 capturing the connector filament, the band both biases the fastener portions 830a, 830b to bring engaged tissue portions together as well as provides additional outward force of the fastener portions and their engaged tissue against the connector filament. Fastener 826 has surface feature 840 to retain the band 834 engaged with fastener portions 830a, 830b. A stem 842 allows the physician to dispense the fastener from the endoscope and is connected with bridge 850 by a frangible connection so it can be disconnected by turning, or the like. Also, fastener 826 can be reloaded in the manner previously described.


Thus, it is seen that fixation system 822 is capable of providing both immediate fixation and promoting long-term fixation. The immediate fixation resists distal migration while the long-term fixation occurs and that long-term fixation is promoted by bringing tissue portions together around the connector so that they can fuse together around the connector. Such long-term fixation may also include a characteristic on wall 712 of esophageal portion 714 and/or cardiac portion 716 such as tissue ingrowth openings (not shown) that facilitates tissue ingrowth at such characteristic. Fasteners 726 and 826 may be made by a variety of biocompatible materials, including a bioabsorbable material.


In an alternative embodiment shown in FIG. 51, an intraluminal device 910 includes an esophageal portion, or member, 914 that is sized and shaped to the distal esophagus, a cardiac portion, or member 916 that is sized and shaped to a portion of the cardiac portion of the stomach and a connector 918 connected with the esophageal and cardiac portions. Connector 918 includes elongated filaments 920a, 920b, which are sized to be positioned at the GE junction and are slightly bowed outwardly as seen in FIG. 51. The outward bow in the filament, which is semi-rigid or rigid, applies outward pressure to the tissue of the GE junction which tends to increase mucosal capture of the connector by tissue at the GE junction in order to further expedite formation of long-term fixation. Also, such outward stress on the GE junction will assist in the placement of immediate fixation by causing mucosa to bulge outwardly where it can be more readily engaged by the fastener 726, 826. While illustrated as a constant readius outward bow, each filament 920a, 920b coule be non-uniformly bowed such as more outwardly bowed closer to esophageal member 914 than further distally or could have one of a variety of different shapes.


Also, struts or filaments 20a-920b may include a therapeutic agent eluting coating that applies a therapeutic agent, such as an anesthesia, or the like. This coating may elute the agent for a limited period, such as two weeks, after deployment, to ensure pain-free embedding of the struts in the recipient. Alternatively, an agent-dispensing reservoir could be at a distal portion of esophageal portion 14-914 to dispense a controlled amount of a therapeutic agent, such as an anesthesia to the tissue engaging the struts. A different type of agent, such as to encourage tissue fibrosis and ingrowth, may be eluted to encourage earlier and stronger long-term fixation.


In another alternative embodiment shown in FIG. 52, an intraluminal device 1010 has an esophageal member 914 shaped to a distal portion of the esophagus, a cardiac member 916 shaped to a portion of the cardiac portion of the stomach and a connector 1018 extending through the esophageal-gastric (GE) pseudo-sphincter. Connector 1018 has a pair of spaced apart elongated members, or struts, 1020a, 1020b extending between the esophageal and cardiac members. Elongated members 1020a, 1020b may be made of a metal such as stainless steel, nitenol or the like or a carbon fiber or the like. In order to enhance and expedite tissue bridging around struts 1020a, 1020b, a bio-absorbable material 1030 is added to each strut. As illustrated in FIG. 52, bio-absorbable material 1030 can be a cylindrical member that surronds the respective strut. The cylindrical member can be assembled around the strut during assembly of the intraluminal device. Alternatively, the cylindrical member may be slit in order to slide the strut into the cylindaical member after assembly of the intraluminal device.


As is known, bio-absorbable material forms collogen/scar tissue as it is absorbed in the surrounding tissue. The bio-absorbable material thus leaves behind a scaffold of collogen in its place along the elongated member. Thus tissue is thus drawn around the strut as the absorbable material is absorbed in order to cause bridging over the elongated member. This causes long-term fixation of the intraluminal device to form much sooner thus limiting time that short term fixation such as suture or other fastener needs to provide sole fixation. When it is desired to explant intraluminal device 1010, elongated members 1020a and 1020b can be separated from cardiac member 916 or esophageal member 914 using techniques previously described and the strut axially withdrawn from the bridging tissue. It should be understood that abosorbable material 1030 can be applied to any elongated member or strut described herein.


Instead of or in addition to a cyclidrical member around the elongated members, bio-absorbable material 1030 can be applied as a coating to the strut(s). Alternatively, the bio-absorbable material can be applied in strips that are wound around the struts. Other application techniques will be apparent to the skilled artisan. Alternatively, the bio-absorbable material can be eluded from the struts.


The bio-absorbable material may be synthetic or biologic. Examples of synthetic bio-absorbable material are that used in Gore Seamguard and Maxon sutures. Examples of biologic bio-absorbable material are Synovis Peristrip and Bovine Pericardium.


With or without a bio-absorbable material applied to the struts 1020a. 1020b, mucosal ablation or other irritating technique could be used to enhance the bodie's response to promote tissue encompassing or bridging over the struts. Such mucosl ablation could be in the form of cautery, laser treatment, ultrasound, nitrogen freezing or other known techniques. Such mucosal ablation enhances the body's response to the bio-absorbable material to more rapidly form collagen.


While the foregoing description describes several embodiments of the present invention, it will be understood by those skilled in the art that variations and modifications to these embodiments may be made without departing from the spirit and scope of the invention, as defined in the claims below. The present invention encompasses all combinations of various embodiments or aspects of the invention described herein. It is understood that any and all embodiments of the present invention may be taken in conjunction with any other embodiment to describe additional embodiments of the present invention. Furthermore, any elements of an embodiment may be combined with any and all other elements of any of the embodiments to describe additional embodiments.

Claims
  • 1. An intraluminal device, comprising: a body having wall portions defining surface portions, said surface portions configured to the size and shape of a mammalian lumen or hollow organ; anda fixation system that is adapted to resist distal migration of the body in the lumen or hollow organ;one of said wall portions defining a cardiac portion that is configured to the size and shape of a cardiac portion of a stomach, another of said wall portions defining an esophageal portion that is configured to the size and shape of a portion of a esophagus, said body having a connector comprising elongated members connected with said esophageal portion and said cardiac portion and configured to pass through the GE junction, at least one of said elongated members made of metal or carbon fiber;said fixation system comprising a bio-absorbable material added to said at least one of said elongated members.
  • 2. The intraluminal device as claimed in claim 1, wherein said bio-absorbable material comprises a sleeve around said at least one of said elongated members.
  • 3. The intraluminal device as claimed in claim 1, wherein said bio-absorbable material comprises a coating applied to said at least one of said elongated members.
  • 4. The intraluminal device as claimed in claim 1, wherein said bio-absorbable material comprises a strip that is wound around said at least one of said elongated members.
  • 5. The intraluminal device as claimed in claim 1 wherein said bio-absorbable material is eluded from said at least one of said elongated members.
  • 6. The intraluminal device as claimed in claim 1 including a suture or a fastener around said at least one of said elongated members providing immediate fixation while said bio-absorbable material is absorbed in tissue surrounding said at least one of said elongated members.
  • 7. The intraluminal device as claimed in claim 1 wherein said at least one of said elongated members comprises an outward shaped bow.
  • 8. The intraluminal device as claimed in claim 7 wherein said at least one of said elongated members comprises a constant radius outward shaped bow.
  • 9. The intraluminal device as claimed in claim 7 wherein said at least one of said elongated members comprises a non-constant radius outward shaped bow.
  • 10. An intraluminal device, comprising: a body having wall portions defining surface portions, said surface portions configured to the size and shape of a mammalian lumen or hollow organ; anda fixation system that is adapted to resist distal migration of the body in the lumen or hollow organ;one of said wall portions defining a cardiac portion that is configured to the size and shape of a cardiac portion of a stomach, another of said wall portions defining an esophageal portion that is configured to the size and shape of a portion of a esophagus, and said body having a connector comprising elongated members connected with said esophageal portion and said cardiac portion and configured to pass through a gastroesophageal (GE) junction, wherein at least two of said elongated members configured to apply outward pressure to tissue of the GE junction and comprise oppositely extending outward shaped bows that extend outwardly beyond said esophageal member.
  • 11. The intraluminal device as claimed in claim 10 wherein said at least two of said elongated members comprises a constant radius outward shaped bow.
  • 12. The intraluminal device as claimed in claim 10 wherein said at least two of said elongated members comprises a non-constant radius outward shaped bow.
  • 13. A method of fixation of an intraluminal device in a mammalian lumen or hollow organ that experiences peristalsis, the intraluminal device having a body with wall portions defining surface portions, said surface portions configured to the size and shape of the mammalian lumen or hollow organ, one of said wall portions defining a cardiac portion that is configured to the size and shape of a cardiac portion of the stomach, another of said wall portions defining an esophageal portion that is configured to the size and shape of a portion of an esophagus said body having a connector comprising of elongated members connected with said esophageal portion and said cardiac portion and configured to pass through the GE junction, said method comprising: applying a bio-absorbable material along at least one of said elongated members and deploying said intraluminal device to the lumen or hollow organ wherein said bio-absorbable material forms a collagen in tissue around said at least one of said elongated members as said bio-absorbable material is absorbed in the tissue around said at least one of said elongated members, causing tissue to be drawn around said at least one of said elongated members and causing bridging over said at least one of said elongated members to form long-term fixation of the intraluminal device at said at least one of said elongated members.
  • 14. The method as claimed in claim 13, wherein said applying comprises forming a sleeve of bio-absorbable material and placing said sleeve around said at least one of said elongated members.
  • 15. The method as claimed in claim 13, wherein said applying comprises applying a coating of said bio-absorbable material to said at least one of said elongated members.
  • 16. The method as claimed in claim 13, wherein said applying comprises winding a strip of bio-absorbable material around said at least one of said elongated members.
  • 17. The method as claims in claim 13 wherein said bio-absorbable material is eluded from said at least one of said elongated members.
  • 18. The method as claimed in claim 13 including applying mucosal ablation of tissue contacting said at least one of said elongated members.
  • 19. The method as claimed in claim 13 including applying a suture or a fastener around said at least one of said elongated members thereby providing immediate fixation while said bio-absorbable material is absorbed in tissue surrounding said at least one of said elongated members.
  • 20. The method as claimed in claim 13 wherein said at least one of said elongated members comprises an outward shaped bow.
  • 21. A method of fixation of an intraluminal device in a mammalian lumen or hollow organ that experiences peristalsis, the intraluminal device having a body with wall portions defining a surface portions, said surface portions configured to the size and shape of the mammalian lumen or hollow organ, one of said wall portions defining a cardiac portion that is configured to the size and shape of the cardiac portion of the stomach, another of said wall portions defining an esophageal portion that is configured to the size and shape of a portion of the esophagus and said body having a connector comprising elongated members connected with said esophageal portion and said cardiac portion and configured to pass through a gastroesophageal (GE) junction, said method comprising at least two of said elongated members comprising oppositely extending outward shaped bows that extend outwardly beyond said esophageal member and applying outward pressure with said at least two of said elongated members on tissue adjacent said at least two of said elongated members.
CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation-in-part of International Patent application No. PCT/IB2017/056838 filed Nov. 2, 2017 which claims priority from U.S. patent application Ser. No. 62/416,865 filed Nov. 3, 2016 and the present application is a continuation-in-part of U.S. patent application Ser. No. 16/146,004 filed Sep. 28, 2018 which is a continuation-in-part of U.S. patent application Ser. No. 15/534,891, filed Jun. 9, 2017, which claims the priority benefits of International Patent Application No. PCT/US2015/067407, filed Dec. 22, 2015, which claims priority from U.S. patent application Ser. No. 62/234,335, filed on Sep. 29, 2015, and U.S. patent application Ser. No. 62/151,150, filed on Apr. 22, 2015, and U.S. patent application Ser. No. 62/115,689, filed on Feb. 13, 2015, and U.S. patent application Ser. No. 62/097,295, filed on Dec. 29, 2014, which are all hereby incorporated by reference herein in their entireties.

US Referenced Citations (206)
Number Name Date Kind
4403604 Wilkinson et al. Sep 1983 A
4607618 Angelchik Aug 1986 A
5234454 Bangs Aug 1993 A
5306300 Berry Apr 1994 A
5366504 Andersen et al. Nov 1994 A
5507755 Gresl et al. Apr 1996 A
5662713 Andersen et al. Sep 1997 A
5741279 Gordon et al. Apr 1998 A
5820584 Crabb Oct 1998 A
6146416 Andersen et al. Nov 2000 A
6264700 Kilcoyne et al. Jul 2001 B1
6280415 Johnson Aug 2001 B1
6312437 Kortenbach Nov 2001 B1
6355070 Andersen et al. Mar 2002 B1
6398802 Yee Jun 2002 B1
6432040 Meah Aug 2002 B1
6447533 Adams Sep 2002 B1
6544291 Taylor Apr 2003 B2
6558400 Deem et al. May 2003 B2
6572627 Gabbay Jun 2003 B2
6595934 Hissong Jul 2003 B1
6656194 Gannoe et al. Dec 2003 B1
6675809 Stack et al. Jan 2004 B2
6736828 Adams et al. May 2004 B1
6740121 Geitz May 2004 B2
6746460 Gannoe et al. Jun 2004 B2
6755869 Geitz Jun 2004 B2
6773440 Gannoe et al. Aug 2004 B2
6800081 Parodi Oct 2004 B2
6802868 Silverman et al. Oct 2004 B2
6845776 Stack et al. Jan 2005 B2
6916332 Adams Jul 2005 B2
6960233 Berg et al. Nov 2005 B1
6981978 Gannoe Jan 2006 B2
6994095 Burnett Feb 2006 B2
6994715 Gannoe et al. Feb 2006 B2
7025791 Levine et al. Apr 2006 B2
7033373 de la Torre et al. Apr 2006 B2
7033384 Gannoe et al. Apr 2006 B2
7037344 Kagan et al. May 2006 B2
7044979 Silverman et al. May 2006 B2
7066945 Hashiba et al. Jun 2006 B2
7083629 Weller et al. Aug 2006 B2
7083630 DeVries et al. Aug 2006 B2
7087088 Berg et al. Aug 2006 B2
7097650 Weller et al. Aug 2006 B2
7097665 Stack et al. Aug 2006 B2
7111627 Stack et al. Sep 2006 B2
7146984 Stack et al. Dec 2006 B2
7152607 Stack et al. Dec 2006 B2
7211114 Bessler et al. May 2007 B2
7220284 Kagan et al. May 2007 B2
7232461 Ramer Jun 2007 B2
7347875 Levine et al. Mar 2008 B2
7431725 Stack et al. Oct 2008 B2
7445010 Kugler et al. Nov 2008 B2
7449024 Stafford Nov 2008 B2
7682330 Meade et al. Mar 2010 B2
7704264 Ewers et al. Apr 2010 B2
7708752 Durgin May 2010 B2
7753870 Demarais et al. Jul 2010 B2
7771382 Levine et al. Aug 2010 B2
7794447 Dann et al. Sep 2010 B2
7815589 Meade et al. Oct 2010 B2
7815591 Levine et al. Oct 2010 B2
7846174 Baker et al. Dec 2010 B2
7922650 McWeeney et al. Apr 2011 B2
7976488 Levine et al. Jul 2011 B2
7981163 Meade et al. Jul 2011 B2
8029455 Stack et al. Oct 2011 B2
8043355 Shin et al. Oct 2011 B2
8100931 Baker et al. Jan 2012 B2
8137301 Levine et al. Mar 2012 B2
8162871 Levine et al. Apr 2012 B2
8282598 Belhe et al. Oct 2012 B2
8372087 Baker et al. Feb 2013 B2
8447403 Sharma et al. May 2013 B2
8506477 Waller et al. Aug 2013 B2
8529431 Baker et al. Sep 2013 B2
8672831 Baker et al. Mar 2014 B2
8721528 Ho et al. May 2014 B2
8778011 Ryan Jul 2014 B2
8784436 Ho et al. Jul 2014 B2
8801599 Baker et al. Aug 2014 B2
8894670 Baker et al. Nov 2014 B2
9055998 Baker Jun 2015 B2
9060844 Kagan et al. Jun 2015 B2
9198789 Baker et al. Dec 2015 B2
9375338 Baker et al. Jun 2016 B2
9414948 Baker et al. Aug 2016 B2
9545326 Baker et al. Jan 2017 B2
9839545 Baker et al. Dec 2017 B2
9872787 Baker et al. Jan 2018 B2
10027194 Tanaka et al. Jul 2018 B2
10182901 Baker et al. Jan 2019 B2
20010011543 Forsell Aug 2001 A1
20010020189 Taylor Sep 2001 A1
20020032487 Dua et al. Mar 2002 A1
20020091395 Gabbay Jul 2002 A1
20030040804 Stack et al. Feb 2003 A1
20030040808 Stack et al. Feb 2003 A1
20030065359 Weller et al. Apr 2003 A1
20030109935 Geitz Jun 2003 A1
20030199989 Stack et al. Oct 2003 A1
20030212450 Schlick Nov 2003 A1
20040044357 Gannoe et al. Mar 2004 A1
20040087976 DeVries et al. May 2004 A1
20040092892 Kagan et al. May 2004 A1
20040106987 Palasis et al. Jun 2004 A1
20040116999 Ledergerber Jun 2004 A1
20040117031 Stack et al. Jun 2004 A1
20040138761 Stack et al. Jul 2004 A1
20040143342 Stack et al. Jul 2004 A1
20040148034 Kagan et al. Jul 2004 A1
20040172141 Stack et al. Sep 2004 A1
20040210111 Okada Oct 2004 A1
20040220682 Levine et al. Nov 2004 A1
20050004582 Edoga et al. Jan 2005 A1
20050043683 Ravo Feb 2005 A1
20050080395 Levine et al. Apr 2005 A1
20050096728 Ramer May 2005 A1
20050125020 Meade et al. Jun 2005 A1
20050192629 Saadat et al. Sep 2005 A1
20050197715 Kugler et al. Sep 2005 A1
20050228504 Demarais Oct 2005 A1
20050245788 Gerber Nov 2005 A1
20050245957 Starkebaum et al. Nov 2005 A1
20050247320 Stack et al. Nov 2005 A1
20050251165 Vaughan et al. Nov 2005 A1
20050251176 Swanstrom et al. Nov 2005 A1
20050283235 Kugler et al. Dec 2005 A1
20060020277 Gostout et al. Jan 2006 A1
20060036293 Whitehurst et al. Feb 2006 A1
20060064120 Levine et al. Mar 2006 A1
20060074473 Gertner Apr 2006 A1
20060089571 Gertner Apr 2006 A1
20060142844 Lowe et al. Jun 2006 A1
20060149307 Durgin Jul 2006 A1
20060155375 Kagan et al. Jul 2006 A1
20060161139 Levine et al. Jul 2006 A1
20060190019 Gannoe et al. Aug 2006 A1
20060247721 Maschino et al. Nov 2006 A1
20060253131 Wolniewicz, III Nov 2006 A1
20060253142 Bjerken Nov 2006 A1
20060264699 Gertner Nov 2006 A1
20060265082 Meade et al. Nov 2006 A1
20070005147 Levine et al. Jan 2007 A1
20070010866 Dann et al. Jan 2007 A1
20070088428 Teichman Apr 2007 A1
20070112409 Wu et al. May 2007 A1
20070123994 Ortiz et al. May 2007 A1
20070166396 Badylak et al. Jul 2007 A1
20070179590 Lu et al. Aug 2007 A1
20070198035 Threlkeld Aug 2007 A1
20070208429 Leahy Sep 2007 A1
20070233221 Raju Oct 2007 A1
20070260112 Rahmani Nov 2007 A1
20070276432 Stack et al. Nov 2007 A1
20070293716 Baker et al. Dec 2007 A1
20080015523 Baker Jan 2008 A1
20080015618 Sonnenschein et al. Jan 2008 A1
20080015633 Abbott et al. Jan 2008 A1
20080065122 Stack et al. Mar 2008 A1
20080065136 Young Mar 2008 A1
20080215076 Baker Sep 2008 A1
20080312678 Pasricha Dec 2008 A1
20090138071 Cheng et al. May 2009 A1
20090177215 Stack et al. Jul 2009 A1
20090187230 Dilorenzo Jul 2009 A1
20090240340 Levine et al. Sep 2009 A1
20090248171 Levine et al. Oct 2009 A1
20090270818 Duke Oct 2009 A1
20100010298 Bakos et al. Jan 2010 A1
20100030017 Baker et al. Feb 2010 A1
20100063518 Baker et al. Mar 2010 A1
20100114124 Kelleher et al. May 2010 A1
20100114130 Meade et al. May 2010 A1
20100198237 Baker et al. Aug 2010 A1
20100256775 Belhe et al. Oct 2010 A1
20100280313 Gasche et al. Nov 2010 A1
20110004146 Priplata et al. Jan 2011 A1
20110009690 Belhe et al. Jan 2011 A1
20110092879 Baker et al. Apr 2011 A1
20110264234 Baker et al. Oct 2011 A1
20120083871 Ryan Apr 2012 A1
20120089168 Baker et al. Apr 2012 A1
20120095497 Babkes et al. Apr 2012 A1
20120191213 Baker et al. Jul 2012 A1
20120191215 Baker et al. Jul 2012 A1
20120203061 Birk Aug 2012 A1
20120289991 Baker Nov 2012 A1
20130123811 Baker et al. May 2013 A1
20130296913 Foote et al. Nov 2013 A1
20130324902 Miller et al. Dec 2013 A1
20140018611 Baker et al. Jan 2014 A1
20140114230 Baker et al. Apr 2014 A1
20140121585 Baker et al. May 2014 A1
20140158747 Measamer et al. Jun 2014 A1
20140309681 Baker et al. Oct 2014 A1
20150025313 Baker et al. Jan 2015 A1
20150039092 Baker et al. Feb 2015 A1
20150182239 Baker et al. Jul 2015 A1
20160038325 Baker et al. Feb 2016 A1
20160151233 Baker et al. Jun 2016 A1
20160324671 Baker et al. Nov 2016 A1
20170172723 Foote et al. Jun 2017 A1
Foreign Referenced Citations (42)
Number Date Country
0760696 Aug 2001 EP
1808888 Jul 2007 EP
2240215 Jan 2014 EP
2660101 Jun 1997 JP
2006-103873 Apr 2006 JP
2007508053 Apr 2007 JP
2011509758 Mar 2011 JP
2045233 Oct 1995 RU
94026119 Aug 1996 RU
2386455 Apr 2010 RU
WO 9322986 Nov 1993 WO
WO 9412136 Jun 1994 WO
WO 0135834 May 2001 WO
WO 0185034 Nov 2001 WO
WO 02060328 Aug 2002 WO
WO 02094105 Nov 2002 WO
WO 2004019826 Mar 2004 WO
WO 2004064680 Aug 2004 WO
WO 2004064685 Aug 2004 WO
WO 2005037152 Apr 2005 WO
WO 2006044640 Apr 2006 WO
WO 2006078672 Jul 2006 WO
WO 2007092390 Aug 2007 WO
WO 2008100984 Aug 2008 WO
WO 2008101048 Aug 2008 WO
WO 2008101078 Aug 2008 WO
WO 2009048398 Apr 2009 WO
WO 2009091899 Jul 2009 WO
WO 2010117641 Oct 2010 WO
WO 2011056608 May 2011 WO
WO 2011063307 May 2011 WO
WO 2011097209 Aug 2011 WO
WO 2011116025 Sep 2011 WO
WO 2012044917 Apr 2012 WO
WO 2012136249 Oct 2012 WO
WO 2012162114 Nov 2012 WO
WO 2013090190 Jun 2013 WO
WO 2013134227 Sep 2013 WO
WO 2015031077 Mar 2015 WO
WO 2016109346 Jul 2016 WO
2018073752 Apr 2018 WO
2018083632 May 2018 WO
Non-Patent Literature Citations (19)
Entry
International Search Report of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US12/38480, dated Jul. 30, 2012.
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US12/38480, dated Nov. 29, 2013.
“Obesity: Super-Sized Medical Device Market”, Start-Up, Mar. 2003, Technology Strategies (Long Article), pp. 1-10 and a cover page.
Andrew S. Lowe, M.D. and Maria B. Sheridan, M.D., “Esphogeal Stenting”, Seminars in Interventional Radiology, vol. 21, No. 3, 2004, pp. 157-166.
“Polyflex® Espohageal Stent”, Silicone Covered Stent, Boston Scientific, three pages (2003).
Andrew F.R. Dixon, Johgn B. Dixon, and Paul E. O'Brien, “Laparoscopic Adjustable Gastric Banding Induces Prolonged Satiety: A Randomized Blind Crossover Study”, The Journal of Clinical Endocrinology & Metabolism , pp. 813-819, 2005.
Roman, S. et al., “Intragastric balloon for ‘non-morbid’ obesity: a retrospective evaluation of tolerance and efficacy,” Obes. Surg., 2004, 14(4), 539-44, abstract, [on-line], [found Apr. 17, 2009, from Pubmed database].
Busetto, L. et al., “Preoperative weight loss by intragastric balloon in super-obese patients treated with laparoscopic gastric banding: a case-control study,” Obes Surg., 2004, 14(5), 671-6, abstract, [on-line], [found Apr. 17, 2009, from Pubmed database].
Summary of Official Action dated Oct. 29, 2009, from the Israel Patent Office in a patent application corresponding to the present application.
Lowe, Andrew S., M.D. and Sheridan, Maria B., M.D., “Esophageal Stenting,” annotated by Israel Patent Office (2004).
Abstract and claims of U.S. Pat. No. 6,960,233 annotated by the Israel Patent Office (Nov. 1, 2005).
Schembre, Drew, “Advances in Esophageal Stenting: the Evolution of Fully Covered Stents for Malignant and Benign Disease,” Adv. Ther., Springer Healthcare, Apr. 1, 2010, pp. 1-13.
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US08/53912, completed Aug. 19, 2009.
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US05/36991, completed Mar. 6, 2006.
S. Fukudo, T. Nomura, M. Hongo, “Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowl syndrome”, Jan. 19, 1998.
D.G. Maxton, D.F. Martin, P.J. Whorwell, M. Godfrey. “Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms”, Aug. 3, 1990.
Dixon et al. “Health Outcomes of Severely Obese Type 2 Diabetic Subjects 1 Year After Laparoscopic Adjustable Gastric Banding”, 2002, Diabetes Care 25:358-363, (Year: 2002).
International Search Report of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/IB2017/056838, dated Mar. 7, 2018.
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/IB2017/056838, dated May 7, 2019.
Related Publications (1)
Number Date Country
20190262156 A1 Aug 2019 US
Provisional Applications (5)
Number Date Country
62416865 Nov 2016 US
62234335 Sep 2015 US
62151150 Apr 2015 US
62115689 Feb 2015 US
62097295 Dec 2014 US
Continuation in Parts (3)
Number Date Country
Parent PCT/IB2017/056838 Nov 2017 US
Child 16400699 US
Parent 16146004 Sep 2018 US
Child PCT/IB2017/056838 US
Parent 15534891 US
Child 16146004 US